Several financial analysts have recently revised their ratings and price targets for Novo Nordisk A/S (NYSE: NVO). Weiss Ratings upgraded the stock from a “sell (d+)” to a “hold (c-)” rating on February 5, 2026. On the same day, BMO Capital Markets maintained its “market perform” rating for the company.
Other analysts have also provided updated assessments, reflecting varying perspectives on the stock’s potential performance. These changes highlight ongoing evaluations of Novo Nordisk’s market position and outlook.
**Why this matters**
Analyst ratings can influence investor sentiment and trading activity. Upgrades or reaffirmations may signal confidence in the company’s business fundamentals, while downgrades can indicate concerns. Monitoring these updates helps investors make informed decisions about their holdings in Novo Nordisk.
Source: NewsData